ID - 841
EFFICACY AND SAFETY OF ISATUXIMAB SUBCUTANEOUS (SC) PLUS CARFILZOMIB AND DEXAMETHASONE (ISA-KD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS OF THE PHASE 2 STUDY IZALCO
P Gurdeepa, C Marcelob, S Fernandac, H Vaniad, DA Meletiose, D Sosanaf, M Jirig, P Ludekh, E Graçai, Q Hangj
a Illawarra Cancer Care Centre, Wollongong, Australia
b Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil
c Hematologia e Hemoterapia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, SP, Brasil
d Department of Hematology and Oncology, Clínica São Germano, São Paulo, Brazil
e Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece
f Department of Hematology and Bone Marrow Transplantation Unit, Evaggelismos General Hospital, Athens, Greece
g Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Olomouc, Czech Republic
h Department of Internal Medicine, Hematology, and Oncology, University Hospital Brno, Brno, Czech Republic
i Hospital de Santa Maria, Centro de Investigação Clínica, Lisboa, Portugal
j Clinical Haematology Service, St Vincent's Hospital, University of Melbourne, Melbourne, Australia
Ver más
